Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06387823
Status:
RECRUITING
Last Update Posted:
2024-06-04
First Post:
2024-03-10
Brief Title:
Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS a Pilot Study of a Prospective Multicenter Double-blind Double-mock Randomized Controlled Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STAR
Brief Summary:
The goal of this clinical trial is to evaluate the efficacy and safety of Sivelestat sodium and dexamethasone in the treatment of patients with moderate to severe ARDS The main questions it aims to answer are
Is Sivelestat sodium more effective in the treatment of patients with moderate to severe ARDS compared with placebo
Is dexamethasone more effective in the treatment of patients with moderate to severe ARDS compared with placebo Participants will receive Sivelestat sodium dexamethasone or placebo Researchers will compare the efficacy and safety of Sivelestat sodium dexamethasone and placebo
Is Sivelestat sodium more effective in the treatment of patients with moderate to severe ARDS compared with placebo
Is dexamethasone more effective in the treatment of patients with moderate to severe ARDS compared with placebo Participants will receive Sivelestat sodium dexamethasone or placebo Researchers will compare the efficacy and safety of Sivelestat sodium dexamethasone and placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None